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Antithrombotic Choice and Timing in 
Patients Presenting with 
Symptomatic Hemorrhagic 
Conversion
Joshua Margolis, Robin Dharia, MD*, Judy Diep, MD
Introduction
• Hemorrhagic conversion is a dangerous complication of 
ischemic stroke1
– Bleeding into infarcted area due to tissue injury
• Anticoagulation therapy for stroke prevention increases the 
risk of hemorrhagic conversion2
• Anticoagulation medications may currently be overused
– Early anticoagulation therapy after ischemic stroke does 
not appear to significantly decrease the risk of recurrent 
embolic events3
• Current guidelines from American Stroke Association 
emphasize the urgent need for additional research on the 





– What are the most significant risk factors for 
hemorrhagic conversion after acute ischemic stroke 
relating to choice and timing of antithrombotic 
therapy?
• Hypothesis
– Commonly used anticoagulants such as Warfarin and 
Aspirin pose a significant risk for hemorrhagic 
conversion, outweighing their protective effects 
against further embolic events in the first two weeks 
after acute ischemic stroke.
Approach & Results
• Medical chart review of patients with hemorrhagic 
conversion at the Jefferson Center City Hospital
– No intervention, just an analysis of previous patient 
outcomes
• Risk factors studied include:
– Antithrombotic therapy
– Medication initiation timing after initial stroke
– Mechanism and location of stroke
– Atrial fibrillation
– Chronic disease (hypertension, renal disease, liver disease)
– Substance abuse
• Multivariate analysis to look for associations among 
the risk factors
Approach & Results
• There is currently insufficient data for a full analysis (n=58)
– Unexpectedly lower rates of patients with hemorrhagic 
conversion
– Difficulties obtaining data due to coding variability
• Initial patients were pulled from a list of intracerebral 
hemorrhage (ICH) patients
– Mostly hemorrhagic strokes rather than conversions
– Not all hemorrhagic conversions are in the system as a 
separate hemorrhagic event
• Interestingly, 25 of the 58 patients bled on aspirin 
monotherapy
• More patient data is needed to draw any statistically 
significant conclusions
Conclusions
• Once more data is collected, the hope is to 
find new associations and evidence that will 
aid in the precise treatment of acute ischemic 
stroke
• We will identify specific antithrombotic 
therapies and timing of therapies that have 
strong associations with hemorrhagic 
conversion
Future Directions
• Now pulling from a list of ischemic stroke 
patients with atrial fibrillation
– Likely to be on anticoagulants --> increased risk of 
hemorrhagic conversion
– Continue to increase sample size
• Develop better evidence-based internal 
guidelines for acute ischemic stroke treatment 
at the Jefferson Comprehensive Stroke Center
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